10-Q: Trinity Capital Q2 2025: Strong Income Growth
Quarterly Report
Trinity Capital Inc. reports a significant increase in net investment income and total investment income for Q2 2025, driven by portfolio growth and strategic financing activities.
Summary
- Total investment income for Q2 2025 was $69.5 million, up from $54.6 million in Q2 2024, and $134.9 million for the six months ended June 30, 2025, compared to $105.1 million for the same period in 2024.
- Net investment income reached $34.8 million in Q2 2025, an increase from $26.7 million in Q2 2024, and $67.2 million for the six months ended June 30, 2025, up from $51.9 million in the prior year period.
- Net increase in net assets resulting from operations was $41.4 million for Q2 2025, compared to $30.8 million for Q2 2024, and $68.5 million for the six months ended June 30, 2025, up from $45.3 million in the prior year period.
- Net realized losses from investments were $(8.3) million in Q2 2025, compared to $(6.5) million in Q2 2024, and $(10.4) million for the six months ended June 30, 2025, versus $(5.1) million for the same period in 2024.
- Net change in unrealized appreciation from investments was $14.9 million in Q2 2025, up from $10.6 million in Q2 2024, and $11.7 million for the six months ended June 30, 2025, a significant improvement from $(1.4) million in the prior year period.
- The total investment portfolio fair value stood at $1,978.3 million as of June 30, 2025, an increase from $1,725.6 million as of December 31, 2024.
- The weighted average effective yield on average investments was 15.7% for Q2 2025 and 15.5% for the six months ended June 30, 2025.
- The weighted average effective interest rate on borrowings was 7.4% for Q2 2025 and 7.5% for the six months ended June 30, 2025.
- The asset coverage ratio was approximately 187.0% as of June 30, 2025, exceeding the 150% regulatory minimum.
- Unfunded commitments totaled $51.6 million across six portfolio companies as of June 30, 2025.
- Loans to three portfolio companies and equipment financings to one portfolio company, with a total cost of $47.8 million and fair value of $15.6 million (0.9% of the debt investment portfolio fair value), were on non-accrual status as of June 30, 2025.
Sentiment
Score: 8
Explanation: The company demonstrated robust financial performance with significant increases in total investment income and net investment income. The expansion of the investment portfolio and positive net unrealized appreciation indicate healthy underlying asset performance. The successful capital raises, including the recent July 2030 Notes, strengthen the company's liquidity and capacity for future investments. The newly granted co-investment exemptive relief order also provides a positive strategic avenue.
Positives
- Total investment income increased significantly to $69.5 million in Q2 2025 from $54.6 million in Q2 2024, demonstrating strong revenue growth.
- Net investment income grew to $34.8 million in Q2 2025 from $26.7 million in Q2 2024, indicating improved profitability.
- Net assets resulting from operations increased to $41.4 million in Q2 2025, reflecting positive operational performance.
- The investment portfolio's fair value expanded to $1,978.3 million as of June 30, 2025, showing continued portfolio growth.
- Net change in unrealized appreciation from investments was positive at $14.9 million in Q2 2025 and $11.7 million for the six months ended June 30, 2025, indicating favorable fair value adjustments in the portfolio.
- The company maintains a strong asset coverage ratio of 187.0% as of June 30, 2025, well above the 150% regulatory requirement.
- Successfully issued $125.0 million in aggregate principal amount of new unsecured 6.750% Notes due 2030 on July 3, 2025, enhancing capital resources.
- Received an exemptive relief order from the SEC on July 8, 2025, permitting co-investment transactions alongside affiliates, which could enhance investment opportunities and diversification.
Negatives
- Net realized losses from investments increased to $(8.3) million in Q2 2025 from $(6.5) million in Q2 2024, and to $(10.4) million for the six months ended June 30, 2025, from $(5.1) million in the prior year period.
- The total cost of loans on non-accrual status increased to $47.8 million as of June 30, 2025, from $43.3 million as of December 31, 2024, indicating a rise in underperforming assets.
- Net asset value per share slightly decreased to $13.27 as of June 30, 2025, from $13.35 as of December 31, 2024.
Risks
- Investments may not have readily available market quotations, leading to valuation uncertainty and potential significant differences between estimated and actual market values.
- Changes in interest rates can impact net investment income, particularly with floating-rate borrowings and investments, as rising rates increase borrowing costs.
- Persistent inflationary pressures could adversely affect portfolio companies' profit margins.
- Investments denominated in foreign currencies are subject to currency exchange rate fluctuations, foreign exchange controls, and potential illiquidity.
- The company's investments are generally illiquid or thinly traded, making it difficult to purchase or sell at desired prices and potentially resulting in substantial discounts.
- Investments in growth-oriented companies, many with limited operating histories, may experience volatile operating results and be affected by changes in government regulations.
- Most borrowers will require additional capital to meet working capital needs and debt service, posing a risk if such capital is not secured.
- Some debt securities are 'covenant-lite,' meaning financial maintenance covenants are not continuously tested, potentially delaying the detection of deteriorating financial conditions.
Future Outlook
The company expects cash and cash equivalents, combined with available borrowings under the KeyBank Credit Facility, to be sufficient for investing activities and operations in the near and long term. It intends to continue paying quarterly distributions to stockholders. The company anticipates continued inflation in the near to medium-term, particularly in the United States and Europe, which could lead to tighter monetary policy and potentially affect portfolio companies' profit margins.
Management Comments
- Our portfolio management team uses an ongoing investment risk rating system to characterize and monitor our outstanding loans and equipment financings.
- Our investment committee reviews the recommendations and/or changes to the investment risk ratings, which are submitted on a quarterly basis to the Board and its audit committee.
- The Board authorized the 2024 Repurchase Program because it believes sustained macroeconomic pressures and other market factors may cause the Company's common stock to be undervalued from time to time, especially relative to the Company's performance and its peers, and that such repurchase demonstrates the Company's stability and strength, including the resilience and creditworthiness of its portfolio.
Industry Context
The company operates as a Business Development Company (BDC), specializing in providing debt and equity financing to growth-oriented, institutional investor-backed companies. This sector is characterized by investments in illiquid securities and sensitivity to interest rate fluctuations. The recent co-investment exemptive relief order from the SEC positions the company to expand its investment capacity and potentially diversify risk through strategic partnerships with affiliates, aligning with broader trends of specialized credit funds seeking flexible investment structures in the venture capital and high-growth ecosystem.
Comparison to Industry Standards
- NA
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Policy Revision | Adopted revisions to valuation policies and procedures to comply with SEC Rules 2a-5 and 31a-4, establishing a framework for determining fair value in good faith. | NA | Enhances transparency and oversight in investment valuation processes, aligning with regulatory standards. |
| Share Repurchase Program Authorization | Board authorized a program permitting the company to repurchase up to $30.0 million of its common stock. | November 7, 2024 | Aims to address potential undervaluation of common stock and demonstrates financial stability, potentially benefiting shareholder value. |
| Exemptive Relief Order | Granted an exemptive relief order from the SEC permitting certain negotiated co-investment transactions alongside affiliates. | July 8, 2025 | Allows for greater flexibility in investment strategies, potentially enhancing investment opportunities and diversification, subject to Board oversight and 1940 Act compliance. |
Legal Proceedings
- No material legal proceedings are currently pending or threatened against the company.
Related Party Transactions
- Certain related parties, including directors, executive officers, and employees, received distributions from the company relating to their shares held.
- Directors and executive officers received restricted stock awards under the 2019 Long Term Incentive Plan and the 2019 Restricted Stock Plan.
- The company co-manages Senior Credit Corp 2022 LLC (the JV) with a specialty credit manager, investing in secured loans and equipment financings originated by the company.
- Trinity Capital Adviser LLC (Adviser Sub), a wholly-owned subsidiary, provides investment advisory services to investment vehicles with external parties, with related expenses allocated from the company.
- The company and a specialty credit manager funded a portion of their capital commitments to EPT 16 LLC, a credit fund that acquires investments originated by the company.
Stakeholder Impact
- Shareholders: Positive impact due to increased net investment income, positive unrealized appreciation, continued distributions, and potential for share repurchases. Dilution from ATM program is a factor, but offset by capital raised.
- Employees: Increased headcount and stock-based compensation plans suggest growth and provide incentives.
- Portfolio Companies: Continued access to debt and equity financing from Trinity Capital, supporting their growth and operational needs.
- Creditors: Strong asset coverage ratio (187.0%) and new debt issuance (July 2030 Notes) indicate robust financial health and ability to meet obligations.
Next Steps
- Continue to make investments in accordance with its investment objective and strategy.
- Pay quarterly distributions to stockholders.
- Potentially enter into additional credit facilities or issue additional securities.
- Repurchase common stock under the 2024 Repurchase Program until November 7, 2025, or until the approved amount is expended.
- Utilize the co-investment exemptive relief order to enter into co-investment transactions alongside affiliates.
Key Dates
| Date | Description |
|---|---|
| January 16, 2020 | Date of initial investment for assets purchased from Legacy Funds as part of Formation Transactions; 2025 Notes issued; Private Common Stock Offering completed. |
| January 29, 2021 | Common stock began trading on Nasdaq Global Select Market. |
| December 5, 2022 | Entered into joint venture agreement with a specialty credit manager to co-manage Senior Credit Corp 2022 LLC. |
| March 16, 2023 | Formed unconsolidated wholly owned subsidiary, Trinity Capital Adviser LLC. |
| June 28, 2024 | Funded a portion of capital commitments to commence operations of credit fund EPT 16 LLC. |
| July 19, 2024 | Issued and sold $115.0 million in aggregate principal amount of September 2029 Notes. |
| August 1, 2024 | Equity investment in Athletic Brewing Company, LLC; Secured loan to Ogee, Inc. |
| August 6, 2024 | Secured loan to Upward Health, Inc.; Secured loan to Lightforce Orthodontics, Inc. |
| August 7, 2024 | Secured loan to Slingshot Aerospace, Inc.; Secured loan to Shoulder Innovations, Inc. |
| August 23, 2024 | Increased maximum aggregate offering price of shares of common stock to be sold through ATM Program to $250.0 million. |
| August 29, 2024 | Secured loan to Mesa Financial, Inc. |
| August 30, 2024 | Secured loan to Beam Technologies, Inc.; Secured loan to Neuros Medical, Inc.; Equity investment in Impulse Space, Inc. |
| September 9, 2024 | Secured loan to RXAnte, Inc. |
| September 13, 2024 | Secured loan to Under Technologies, Inc.; Equipment financing to Impulse Space, Inc. |
| September 16, 2024 | Equity investment in Knockaway, Inc. |
| September 19, 2024 | Equipment financing to Electric Hydrogen Co. |
| September 23, 2024 | Secured loan to Tarana Wireless, Inc. |
| September 27, 2024 | Equipment financing to Astranis Space Technology Corporation. |
| September 30, 2024 | Equipment financing to Apiject Holdings, Inc. |
| October 1, 2024 | Secured loan to Metabolon, Inc. |
| October 2, 2024 | Equity investment in Maxwell Financial Labs, Inc.; Secured loan to Maxwell Financial Labs, Inc. |
| October 3, 2024 | Secured loan to SOCi, Inc. |
| October 18, 2024 | Equity investment in Busbot, Inc.; Secured loan to Vox Media Holdings, Inc. |
| October 21, 2024 | Equipment financing to Form Energy Inc. |
| October 22, 2024 | Equipment financing to Cirrascale Cloud Services, LLC. |
| October 29, 2024 | Entered into note purchase agreement for Series A Senior Notes. |
| October 30, 2024 | Secured loan to Zandivio PLC. |
| October 31, 2024 | Secured loan to Elucent Medical, Inc. |
| November 4, 2024 | Secured loan to Eyelit Technologies, Inc.; Secured loan to Silk Technologies, Inc. |
| November 6, 2024 | Equity investment in Crusoe Energy Systems LLC. |
| November 7, 2024 | Board authorized $30.0 million share repurchase program. |
| November 14, 2024 | Secured loan to Wisetack, Inc.; Equipment financing to Electric Hydrogen Co. |
| November 25, 2024 | Secured loan to Hometown Ticketing, Inc. |
| November 27, 2024 | Secured loan to Under Technologies, Inc. |
| December 12, 2024 | Equipment financing to Form Energy Inc. |
| December 18, 2024 | Warrant investment in Medical Sales Training Holding Company Two. |
| December 20, 2024 | Secured loan to Centivo Corporation. |
| December 23, 2024 | Equipment financing to Nucleus RadioPharma, Inc. |
| December 26, 2024 | Equipment financing to Uveye, Inc. |
| December 27, 2024 | Secured loan to Eyelit Technologies, Inc.; Equipment financing to Impulse Space, Inc. |
| December 30, 2024 | Equity investment in Rinse, Inc. |
| January 16, 2025 | 2025 Notes matured and were repaid in full. |
| January 21, 2025 | Secured loan to Neurolens, Inc. |
| January 24, 2025 | Secured loan to Cagent Vascular, Inc. |
| January 29, 2025 | Equipment financing to Cellares Corporation. |
| February 3, 2025 | Secured loan to Centivo Corporation. |
| February 10, 2025 | Entered into open market sale agreement for ATM March 2029 Notes and ATM September 2029 Notes. |
| February 11, 2025 | Equipment financing to Sortera Technologies, Inc. |
| February 12, 2025 | Equipment financing to Impulse Space, Inc. |
| February 20, 2025 | Holders of Convertible Notes exercised conversion right, repaid in cash. |
| February 26, 2025 | Secured loan to Xytech Systems, LLC. |
| February 27, 2025 | Equity investment in Cabernet AI, Inc. |
| March 14, 2025 | Board approved grants of non-statutory stock options. |
| March 20, 2025 | Equipment financing to Rocket Lab USA, Inc. |
| March 21, 2025 | Secured loan to Vital Connect, Inc. |
| March 24, 2025 | Secured loan to CMR Surgical Limited. |
| March 26, 2025 | Equity investment in Digilens, Inc. |
| April 10, 2025 | Secured loan to B.Well Connected Health, Inc. |
| April 14, 2025 | Equity investment in Get Spiffy, Inc. |
| April 23, 2025 | Secured loan to SOCi, Inc. |
| April 24, 2025 | Secured loan to Lendflow, Inc. |
| April 28, 2025 | Secured loan to Maple Raptor Acquisition Inc. |
| May 2, 2025 | Equipment financing to Evo Equipment Leasing, LLC. |
| May 6, 2025 | Secured loan to Rarefied Atmosphere, Inc. |
| May 7, 2025 | Secured loan to Mesa Financing I, LLC. |
| May 9, 2025 | Equity investment in Impulse Space, Inc. |
| May 14, 2025 | Secured loan to Knockaway, Inc. |
| May 15, 2025 | Equipment financing to Uveye, Inc. |
| May 16, 2025 | Secured loan to Steno Agency, Inc. |
| May 23, 2025 | Equipment financing to Evo Equipment Leasing, LLC. |
| May 27, 2025 | Secured loan to Paytient Technologies, Inc. |
| May 28, 2025 | Secured loan to Swimlane, Inc. |
| May 30, 2025 | Secured loan to K2View Inc. |
| June 3, 2025 | Secured loan to ServiceTrade, Inc. |
| June 10, 2025 | Secured loan to Inshur, Inc. |
| June 11, 2025 | Secured loan to Kymeta Corporation. |
| June 13, 2025 | Secured loan to Centivo Corporation. |
| June 20, 2025 | Secured loan to Eyelit Technologies, Inc. |
| June 24, 2025 | Secured loan to Okami Medical, Inc. |
| June 25, 2025 | Equipment financing to Impulse Space, Inc.; Secured loan to Beam Technologies, Inc.; Equipment financing to Uveye, Inc. |
| June 27, 2025 | Equipment financing to AST & Science, LLC. |
| June 30, 2025 | Secured loan to Renalogic Holdings, Inc. |
| July 3, 2025 | Issued and sold $125.0 million in aggregate principal amount of unsecured 6.750% Notes due 2030 (July 2030 Notes). |
| July 8, 2025 | Granted co-investment exemptive relief order from the SEC. |
| August 4, 2025 | Last reported closing sales price of common stock was $14.95 per share. |
| August 6, 2025 | Filing date of the Quarterly Report on Form 10-Q. |
Recommendation
buyThe company demonstrated robust financial performance with significant increases in total investment income and net investment income. The expansion of the investment portfolio and positive net unrealized appreciation indicate healthy underlying asset performance. The successful capital raises, including the recent July 2030 Notes, strengthen the company's liquidity and capacity for future investments. The newly granted co-investment exemptive relief order provides a strategic advantage for future growth and diversification. While there are some non-accrual loans and realized losses, the overall trajectory and strategic moves suggest a strong outlook for the company.
Keywords
BDC, Business Development Company, investment portfolio, secured loans, equipment financing, venture lending, growth companies, net investment income, asset coverage ratio, capital raise, unfunded commitments, non-accrual loans, interest rate risk, valuation risk, co-investment, SEC filing, 10-Q, financial results
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.